SCHEMBL2196176

SCHEMBL2196176

N=C(N)NCCC[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(N)=O

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
NPY4R P50391 15/20 0.74
NPY1R P25929 9/20 0.74
NPY5R Q15761 8/20 0.74
NPY2R P49146 5/20 0.74
KISS1R Q969F8 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13563451 0.99 NPY4R (0.72) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL29641080 0.96 NPY4R (0.80) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL13563459 0.95 NPY4R (0.77) NPY4RNPY1RNPY5RNPY2R
SCHEMBL15681487 0.95 NPY4R (0.77) NPY4RNPY1RNPY5RNPY2R
SCHEMBL8975655 0.94 NPY4R (0.67) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL29637467 0.94 NPY4R (0.66) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL29641154 0.94 NPY4R (0.76) NPY4RNPY1RNPY5RNPY2R
SCHEMBL13563450 0.94 NPY4R (0.64) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL3356931 0.94 NPY4R (0.64) NPY4RNPY1RNPY5RNPY2RKISS1R
SCHEMBL3356923 0.94 NPY4R (0.64) NPY4RNPY1RNPY5RNPY2RKISS1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2019-03-07 US disclosed
US-9682153-B2 Polymer conjugates of therapeutic peptides NEKTAR THERAPEUTICS (US) 2017-06-20 US disclosed
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NEKTAR THERAPEUTICS 2016-01-28 US disclosed
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE NEKTAR THERAPEUTICS (US) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160022828-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP NPY4R 567/4885NPY1R 544/4885NPY5R 588/4885
US-20190070251-A1 POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES NGLY1, CD44, IAPP NPY4R 567/4885NPY1R 544/4885NPY5R 588/4885
US-20110171312-A1 MODIFIED THERAPEUTIC PEPTIDES, METHODS OF THEIR PREPARATION AND USE DNPEP, VIP, PTMS NPY4R 915/4885NPY1R 631/4885NPY5R 1066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.